| Literature DB >> 24129344 |
Steven R Schuster1, K Martin Kortuem2, Yuan Xiao Zhu2, Esteban Braggio2, Chang-Xin Shi2, Laura A Bruins2, Jessica E Schmidt2, Greg Ahmann2, Shaji Kumar3, S Vincent Rajkumar3, Joseph Mikhael2, Betsy Laplant4, Mia D Champion2, Kristina Laumann4, Bart Barlogie5, Rafael Fonseca2, P Leif Bergsagel2, Martha Lacy3, A Keith Stewart2.
Abstract
Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma (MM). We demonstrate here that no patient with very low CRBN expression responded to IMiD plus dexamethasone therapy. In 53 refractory MM patients treated with pomalidomide and dexamethasone, CRBN levels predict for decreased response rates and significant differences in PFS (3.0 vs. 8.9 months, p<0.001) and OS (9.1 vs. 27.2 months, p=0.01) (lowest quartile vs. highest three quartiles). While higher CRBN levels can serve as a surrogate for low risk disease, our study demonstrates that low CRBN expression can predict resistance to IMiD monotherapy and is a predictive biomarker for survival outcomes.Entities:
Keywords: Biological markers; Cereblon; Gene expression profiling; Immunomodulatory drugs; Multiple myeloma
Mesh：
Substances：
Year: 2013 PMID： 24129344 PMCID： PMC3905958 DOI： 10.1016/j.leukres.2013.08.015
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156